Immunity and inflammation are important parameters of the pathophysiology of stroke, a destructive illness that is the second most common cause of death worldwide. Following ischemic stroke, neuroinflammation plays a critical role in neurodegeneration and brain injury. MicroRNAs (miRNAs) are a class of endogenously expressed, noncoding RNA molecules that function to inhibit mRNA translation. Recent studies demonstrate that miRNAs are key regulators of inflammatory processes contributing to ischemic stroke injuries. Several miRNAs, and their target genes, have been shown to play a critical role in the innate inflammatory responses mediated by immune cells. The capacity of miRNAs to regulate several target genes demonstrates their exceptional importance in neuroinflammatory therapeutics following ischemic stroke. In this review, we focus on the miRNAs associated with ischemic neuroinflammation and describe the potential of miRNAs as biomarkers of neuroinflammation and promising therapeutic agents for modulation of deleterious inflammatory responses following ischemic stroke.
INTRODUCTION Stroke
Stroke is the second cause of death and a major cause of physical disability: approximately 15 million people have a stroke every year, and there are about 5 million deaths worldwide (1) . According to the underlying pathology, stroke may be classified as ischemic or hemorrhagic stroke (2) . Ischemic stroke accounts for 85% of all strokes, whereas hemorrhagic stroke is responsible for 15% of them (3) . Recently, considerable progress in understanding mechanisms of stroke pathophysiology has been made, especially in ischemic stroke. This has led to the exploration of more than thousand molecules with brain-protective properties from experimental models and to the implementation of more than 250 clinical trials, which highlights a critical need for new approaches to the development of therapies for ischemic stroke (4). Despite all these improvements, translation of this knowledge into effective therapies has failed. Reperfusion induced by tPA (tissue plasminogen activator) is the only appropriate thrombolytic agent available for stroke treatment (5, 6); however, due to a short time window this treatment is only suitable for a minority (<10%) of stroke patients (7).
Inflammation Following Stroke
Lack of blood flow, oxygen and glucose following cerebral artery occlusion and cerebral ischemia (8), and subsequent reperfusion of the ischemic tissue causes a cascade of cellular and molecular events leading to the ischemic damage and irretrievable cerebral injury (9). Neurons confronting hypoxia-ischemia become quickly dysfunctional or die because they are more vulnerable than glia and vascular cells when exposed to hypoxia (10). Ischemia leads to several pathophysiological processes such as excitotoxicity, oxidative and nitrative stress, inflammation and apoptosis, which are seriously injurious to neurons, glia and endothelial cells (11) (12) (13) (14) . These pathophysiological processes are interlinked, triggering each other in a positive feedback loop that terminates in neuronal cell death and brain damage (15).
Mounting evidence indicates that inflammation and immune responses have deleterious effects during and after stroke by activating various cascades of damage (16). However, several lines of evidence show that inflammatory mechanisms also have beneficial effects (17) (18) (19) . Experimental models of stroke show that lymphocyte populations and inflammatory mediators have key roles in the progression of brain injuries and neurological deficits (20-24). Immune system agents are intimately involved in all stages of ischemic processes including acute intravascular events initiated via interruption of the blood supply and parenchymal processes resulting from brain injury and the following tissue repair. In turn, the ischemic brain exerts a strong suppressive effect on lymphoid organs by the autonomic nervous system, and this action promotes intercurrent infections, which are a major determinant factor in the stroke morbidity and mortality. Therefore, the immune system is important for the survival of people after stroke (25, 26) .
After ischemic stroke, most therapeutic methods have focused on safeguarding neurons from the main pathophysiological processes, such as inflammation and apoptosis that might otherwise occur in the penumbra zone, and this area is the target for therapeutic agents. The periphery of the ischemic region, the so-called ischemic penumbra, is where neurons are salvageable and metabolically active and where cell death occurs more slowly because revascularization and blood flow arises from adjacent vascular territories (collateral flow) (9, 27-29).
MicroRNAs
MicroRNAs (miRNAs) are endogenous 22 nucleotide (nt) non-protein-coding RNAs, which have led to an outburst of new mechanistic hypotheses in human disease. miRNAs play important regulatory roles in animals and plants through targeting mRNAs for cleavage or degradation, or inhibition of translation (30, 31). miRNAs have been proposed to regulate as much as one-third of protein-coding genes in humans (32), and have been implicated in the regulation of a diverse biological processes and diseases such as neuronal development, cellular differentiation, synaptic plasticity, proliferation, metabolism, apoptosis, neurodegenerative diseases, and oncogenesis (33-39). miRNAs are initially transcribed from genomic DNA, and RNA polymerase II is responsible for transcription of primary miRNA (pri-miRNA), which may contain more than one miRNA (40). Pri-miRNAs can be thousands of base pairs in length and consist of at least one hairpin loop, which are processed by the endonuclease Drosha, and its binding partner DGCR8, and which generates a precursor miRNA (pre-miRNA) (41, 42). The pre-miRNA is transported from the nucleus into the cytoplasm by exportin-5 with a Ran-GTPdependent mechanism. Pre-miRNA undergoes cleavage by RNase III enzyme (Dicer) to form a duplex of the mature miRNA strand, which is generally biologically active (43-45).
Several studies have revealed that biological functions of miRNAs are extremely dependent on the cellular context and the precise link between miRNAs and the consequences of stroke should be discussed only within a specific cellular context. The studies showed that miRNAs have participated as key mediators in the molecular processes underlying cerebral ischemia and related diseases (46-49). Also, it has been clarified that a number of miRNAs target several genes that are involved in postischemic inflammation (50, 51). Therefore, in the present study, we review all available relevant articles regarding miRNAs and poststroke inflammation in order to explain the complex link between inflammatory responses and miRNAs following brain stroke. The information about poststroke inflammation-miRNAs system may be used for therapeutic and diagnostic methods in stroke treatment.
Intervention of miRNAs in Ischemic Stroke Pathogenesis
Given the complexity of the CNS, it is to be expected that a number of brain-enriched miRNAs have appeared as possible regulators of homeostatic function and, in pathological disorders such as stroke, as mediators of neurodegeneration and neuroinflammation (52). In stroke etiology, miRNAs modulate pathogenic processes including atherosclerosis, hyperlipidemia, hypertension, and plaque rupture (53). According to the etiologies, ischemic stroke can be further classified into four main categories as follows: small vessel disease, athero-thrombotic, cardio-embolic, and undetermined causes (2) . Several pathogenic processes are involved in ischemic stroke progression which include excitotoxicity, oxidative stress, inflammation, and apoptosis (54). It has been demonstrated that a number of miRNAs target several pathogenic processes that are involved in ischemic stroke progression, and these pathological cascades include blood-brain barrier (BBB) disruption, excitotoxicity, oxidative stress, inflammation, and caspase-mediated cell death signaling (50, 51) (Table) . The future of gene therapy offers new therapeutic strategies directed by successfully implemented miRNA therapeutics that regulate large sets of genes in related pathways of the ischemic stroke cascade (53).
IMMUNOLOGICAL FEATURES OF STROKE
At stroke onset, the immune responses can contribute to ischemic stroke pathogenesis, also multiple lymphocyte populations and their released proteins have a significant role in cell death and brain damage following ischemic stroke (21, 22). Before stroke onset, unusual immune responses can trigger inflammation within and around vessel walls, thereby causing thrombosis, changing vascular reactivity, boosting atherosclerosis, and eventually cerebral tissue pathogenesis (55, 56). Atherosclerotic plaques can develop by the actions of leukocyte cells (which cause inflammation) and occlusion of arteries, resulting in ischemic events (57). Moreover, stroke incidence can be affected via inflammatory processes through several mechanisms, including thrombosis, vasculopathy, and, most often, by atherosclerosis (55, 58-62).
Stroke onset quickly induces primary irreversible brain tissue damage in the form of immune-inflammatory responses within the brain and its vessels. Secondary processes, including excitotoxicity, oxidative stress and mitochondrial dysfunction, then expand this damage to the penumbra area. Brain-intrinsic microglia, such as brain resident macrophages, are the first immune cells that respond to these events, and are followed by leukocytes that infiltrate into the brain through the compromised (BBB). Dying neurons release chemokines that guide the entry of these leukocytes (63, 64) . Inflammation can trigger various processes in the cerebral microvasculature, including BBB disruption (partly mediated by matrix metalloproteinases [MMPs]), binding of red blood cells to the endothelial cells, and platelet aggregation (55, (58) (59) (60) (61) (62) .
Following ischemia, recruited immune cells such as neutrophils, natural killer cells, macrophages, and dendritic cells release mediators that activate nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) pathways, which damage endothelial cells (65) (66) (67) . Conversely, several experimental studies propose that preinfections might promote neurogenesis, increasing anti-inflammatory responses, suppressing macrophage accumulation within atherosclerotic injuries, and having a protective role by producing free radical scavengers and neuroprotective molecules, which thus cause a form of preconditioning (68) (69) (70) (71) (72) . Nevertheless, the overall effect of previous inflammation on stroke occurrence is deleterious and indicates that inflammation is an important therapeutic target for stroke inhibition.
MIRNAS IN THE EARLY PHASE OF ISCHEMIC INFLAMMATORY SIGNALS
Immediately after vessel occlusion and ensuing hypoxia (vascular shear stress induced by stagnant blood flow and altered rheology) there is consequent activation of the inflammatory process in the cerebral intravascular compartment. The coagulation cascade activated through changes in shear stress and production of reactive oxygen species (ROS), which lead to activation of platelet and endothelial cells (73) (74) (75) (76) . This is followed occlusion of brain microvessels by fibrin formation in which platelets and leukocytes are trapped (77, 78) . Thrombin exerts a variety of cellular effects on endothelial cells such as expression of adhesion molecules, following activation of protease-activated receptors and NF-kB (nuclear factor kappa B). Thrombin is also a chemotaxin for monocytes and neutrophils (79) and activates components of the complement system (C3 and C5), the humoral branch of innate immunity, and can disrupt endothelial barrier function (80) . The complement system contributes to the pathobiology of stroke and its activation leads to unfavorable outcomes (81, 82) . miRNAs may regulate thrombus formation in ischemic stroke, and there are miRNAs that regulate coagulation and platelets (32, 33). Tissue factor produced mainly from monocytes is a main element in the coagulation cascade. miR-19a decreases tissue factor activity and inhibits clot formation by acting on the TFPI (tissue factor pathway inhibitor). Therefore, miR-19a may modulate thrombus formation after ischemic stroke. Further, SERPINE1 (plasminogen activator inhibitor-1) codes for the main inhibitor of tPA and uPA (urokinase), which act on plasminogen to increase fibrinolysis. In ischemic stroke, miR-148a and miR-19a may regulate the activity of endogenous tPA via targeting SERPINE1. Also, in ischemic stroke several coagulation factors could be regulated by some miRNAs, including miR-let-7i that regulates thrombin, miR-122 targets coagulation factor VIII, as well as miR-148 and miR-19a that regulate coagulation factor III (83) . In the minutes after ischemia, the adhesion molecule P-selectin spreads onto the platelets and the endothelial surface (84) , and proinflammatory signals are quickly initiated. It is revealed that tumor necrosis factor (TNF), as a proinflammatory cytokine, induces expression of E-selectin, ICAM-1, and VCAM-1 on the endothelial cell surface that binds leukocytes (85, 86) .
In the endothelial cells some of miRNAs are expressed via vascular endothelial growth factor (VEGF) and they regulate cell growth, survival, and angiogenesis (87) (88) (89) . Other miRNAs are expressed in a variety of cell types by different proinflammatory agents (90) (91) (92) (93) (94) . It is reported that induction of endothelial adhesion molecules by TNF can be regulated by miRNAs that are induced by TNF. Specifically, TNF-induced miRNAs miR-31 and miR-17-3p target E-selectin and ICAM-1, respectively. It was shown that adhesion of neutrophils to cultured endothelial cells increased via specific antagonism of these TNF-induced miRNAs, which suggests that these miRNAs act as a negative feedback control for inflammation (85) . It has been shown that miR-126, an endothelial cell-restricted miRNA, modulates TNF-induced VCAM-1 expression (95) . Selectins attracts leukocytes to the endothelial surface by interacting with P-selectin glycoprotein ligand-1 that is expressed on leukocytes. Also, platelet P-selectin binds to leukocytes and helps cluster formation that leads to the intravascular obstruction, and contributes to cerebral ischemic damage (96) .
Nitric oxide (NO) is a powerful vasodilator and inhibitor of leukocyte adhesion to the endothelium and thus a GLT-1, glutamate transporter-1; PUMA, p53 upregulated modulator of apoptosis; NR2B and NR2A, glutamate NMDA receptor subunits; MDA, malondialdehyde; Nrf2, nuclear factor erythroid-2 related factor 2; SOD, superoxide dismutase; MnSOD, manganese superoxide dismutase; COX2, cyclooxygenase 2; ROS, reactive oxygen species; SOCS1, suppressor of cytokine signaling 1; MyD88, myeloid differentiation primary response gene 88; MMP-9, metalloproteinases 9; FasL, Fas ligand; FAP-1, Fas associated protein-tyrosine phosphatase 1; BCL2L11, Mcl-1, Bcl-2 and Bcl-w, antiapoptotic Bcl-2 family; HSPA12B, heat shock protein A12B; iASPP, inhibitory member of the apoptosis-stimulating proteins of p53 family.
suppressor of platelet accumulation. It is revealed that bioavailability of NO in endothelial cells is reduced by oxidative stress (84) , which aggravates intravascular plugging and consequently decreases blood flow to the ischemic zone, thus exacerbating the ischemic insult (97, 98) . Moreover, oxidative stress causes more microvascular occlusions by contraction of pericytes, which are contractile cells in capillaries (99) . Studies have also demonstrated that miR-424 reduces ROSinduced injury in neurons which results in neuroprotection against ischemic oxidative damages (100).
It has been demonstrated that miR-155 inhibition results in increasing eNOS (endothelial nitric oxide synthase) expression, NO production, and lessening of vascular inflammation (101, 102) . Following ischemic stroke, nitric oxide synthase can decrease rates of neuronal injury through improvement of blood flow (103) . It is demonstrated that miR-155 function is the promotion of T-cell-dependent tissue inflammation, suggesting that miR-155 might be a promising therapeutic target for the treatment of inflammatory disorders (104) .
Following acute ischemic stroke, expression of genes that are involved in leukocyte adhesion and BBB disruption have been demonstrated (105) (106) (107) (108) . Macrophages and mast cells are present in the perivascular space activated by ischemia and reperfusion. In this situation, vasoactive agents such as histamine, proteases (tryptase, chymase, MMP2, and MMP9) and TNF are produced and released by the mast cells, whereas proinflammatory cytokines, chemokines, ROS and NO are generated by stimulated M1 macrophages (109) (110) (111) (112) (113) . These proinflammatory cytokines (IL-1b, IL-12, IL-23, and TNF) promote the infiltration of leukocytes (neutrophils, lymphocytes, and monocytes) through the expression of endothelial adhesion molecules and BBB disruption (111) .
There is evidence that miRNAs may regulate genes that contribute in the leukocyte following ischemic stroke (83) . miRNAs can also control the expression of MMPs, which are involved in BBB disruption (114) . miR-320 targets transcription factor ETS2 that regulates the expression of MMP-9, MMP-3, MMP-13, and TNF genes, which are important in leukocyte extravasation following stroke (115, 116) . It has been observed that in all stroke patients with especially good outcomes miR-320 is marginally downregulated, which could also lead to antiapoptotic processes (117) . Furthermore, infarct volume in cerebral ischemia could be reduced by anti-miR320a, which causes by increased concentrations of aquaporins-1 and 4 (AQP1 and AQP4) mRNA and protein expression. AQP1 and AQP4 are a family of transmembrane proteins involved in movement of water into and out of an ischemic brain (118) . It has been shown that protection against cytotoxic edema caused by water intoxication and permanent focal cerebral ischemia made by AQP4 knockouts in mice had a deleterious effect and led to vasogenic brain edema (119, 120) . miRNA-19a regulates MMP-3 via toll-like receptor-2 (TLR2) (121) , and this miRNA may contribute to BBB disruption and vascular remodeling poststroke (122) . It has been shown that miR-491-5p decreases the levels of MMP-9 expression and inhibits cellular invasion (123) . miR-29b represses MMP-2 and MMP-9 at the transcriptomic level in the peri-infarct region at 72 hours following stoke. Thus, it is likely that miR-29b action would be beneficial in the context of stoke (124) . Following stroke, lower levels of MMPs will result in less BBB breakdown and should act to limit progression of the infarct size (125, 126) (Fig. 1) .
MIRNAS INTERPLAY IN THE STAGE OF INNATE IMMUNITY FOLLOWING ISCHEMIC CELL DEATH
Dying and dead cells play a key role in the postischemic inflammation by releasing danger signals that activate immune system. These danger signals represent a variety of molecular signals released from intracellular compartments or generated by the action of lytic enzymes escaping from dead cells on matrix proteins, which are usually called dangerassociated molecular pattern molecules (DAMPs) (127) . Some of these signals (eg, purinergic signals) are released by cells under stress conditions and contribute to the fine-tuning of the inflammatory and immune responses (128) .
One of the earliest inflammatory processes in the brain parenchyma might be DAMPs, including purines (ATP, UTP, and their catabolites), high mobility group binding protein 1, heat shock proteins, peroxiredoxins, and mitochondrialderived N-formyl peptides. DAMPs activate their receptors, including Toll-like receptors and scavenger receptors on microglia, astrocytes, perivascular macrophages, and brain endothelial cells (129) (130) (131) (132) (133) . These receptors induce inflammatory responses in resident brain cells and infiltrating leukocytes, which lead to inflammatory cell death (21). In the first hours of ischemia, microglia respond to the altered environment, and increase their contact with neurons experiencing excitotoxic calcium overload (134) . Microglia activation leads to release of inflammasome-mediated IL-1b, and TNF production, which feed back into the inflammatory cascade by inducing cytokine and chemokine production in endothelial cells and astrocytes (135) .
In the microglial cells, expression of TLR4 is upregulated after ischemia (136) . TLR4 expression is negatively regulated by miR-181c and suppresses proinflammatory products, such as TNF-a, IL-1b, and iNOS (137) . The expression of TNF-a and IL-1b induced by miR-155 through upregulation of TLR4 downregulates the expression of inflammatory mediators such as suppressor of cytokine signaling 1 and the myeloid differentiation primary response gene 88 following ischemic stroke (138) . In response to the proinflammatory stimuli such as IFN-c(interferon gamma) and TNF-a, the expression of miR-155 is upregulated in the microglia, macrophages, and monocytes (139) (140) (141) .
Dysfunctions of reactive astrocytes are essential for the pathological processes of stroke (142) . Several studies have shown that endoplasmic reticulum (ER) stress and inflammation in astrocytes are important mechanisms involved in brain damage (143) (144) (145) . Expression of miR-7 could modulate ERassociated degradation via targeting the 3 0 UTR of Herpud2, which participates in the process of ER-associated degradation and mediates ER stress-induced inflammation. Ischemic stroke could downregulate miR-7 and upregulate Herpud2, which drives ER stress by upregulating ER stress proteins including Caspase-12, GRP78, and CHOP (146). 
Extracellular ATP abundance increased after ischemic events such as plasma membrane damage, neuronal and glial depolarization (147) (148) (149) . The role of the purinergic receptors in the microglial inflammatory response has largely focused on P2X7, and activation of these receptors led to releasing of proinflammatory mediators. It was shown that P2X7 pharmacologic blockade led to decreasing of ischemic damage (150) (151) (152) (153) . Importantly, ATP was reported to activate inflammasome, which are large multimolecular complexes that activate caspase-1 and induces IL-1b production (154) . Moreover, P2Y12 as G 1 -coupled ATP receptor is also present on microglia, and its activation leads to microglial migration toward the source of ATP and ADP nucleotides (155) . Recent studies have shown that P2Y12 contributes to ischemic-related inflammation through increasing microglial migration and potentiation of neurotoxicity (156) . It has also been demonstrated that deficiency or inhibition of microglial P2Y12 could protect against brain ischemia (157) 
Recent studies suggest that miRNAs modulate purinergic receptors, and miRNAs are emerging as effective translational regulators of purinergic receptors such as P2X7 (158) . It has been shown that targeting of miRNA-22 may prevent inflammation in the brain via posttranscriptional regulation of P2X7 receptors (159) . Also, UTP and ATP reduced endothelial inflammation through miR-22-induced ICAM-1 inhibition, which is involved in adhesion and transendothelial migration of immune cells to tissues (160) .
Interaction between neurons and microglia is possible via surface protein CD200 that is expressed in neurons, with CD200R on microglia (161) . Postischemic loss of CD200 may disrupt this interaction and promote microglial activation (162) . Also, CX3CL1 (fractalkine), a chemokine that is expressed by neurons, interacts with CX3CR1 on the microglial surface, and suppresses microglial activation. Thus, loss of fractalkine following neuronal injury leads to increased microglial activation in several inflammatory conditions (163) . Following chronic lung inflammation, inflammatory cytokines such as IL-1b and TNFa stimulate release of miR-223 in monocyte cells. Increased levels of miR-223 reduce both expression and activity of histone deacetylase 2, which leads to upregulation of fractalkine expression that, in turn, might cause more monocytes to adhere the lung endothelium (164) . Furthermore, miR-223 is hyperexpressed in the circulating blood of acute ischemic stroke patients, and it has great potential as a novel therapeutic target for ischemic stroke (165) (Fig. 1) .
MIRNAS AND INNATE IMMUNE CELLS FOLLOWING ISCHEMIC STROKE miRNAs, Microglia and Macrophages
Ischemia activates microglia and monocyte-derived macrophages that release a variety of cytotoxic and/or cytoprotective substances. Reducing the proliferation of microglia/ macrophages increased ischemic brain injury and reduced expression of the neurotrophic cytokine insulin-like growth factor 1 (IGF-1) in mice models (166) . In addition, the neuroprotective effects of microglia are exerted by producing IL-10, TGF-b (21), and generating brain-derived neurotrophic factor (BDNF). However, following ischemia, activated microglial cells distribute proinflammatory cytokines such as TNF-a, IL1b, IL-6, and other potential cytotoxic molecules such as prostanoids, ROS, and NO (63, 167, 168) . Although the initial purpose of microglial activation is the brain's effort to protect neurons, the overactivation of microglia results in deleterious inflammation and increasing the probability of neuronal death (169) (170) (171) . Therefore, several reports demonstrated that suppression of the microglial cells reduced postischemic damage (172, 173) . Exosomes and microvesicles that are released from reactive microglia carrying IL-1b, which is a processing enzyme for caspase-1, and the P2X7 receptor that may increase inflammatory reactions throughout the brain tissue (174) . Furthermore, monocyte-derived macrophages develop from monocytes after infiltration into the brain parenchyma and the expression of C-C chemokine receptor 2 and C-X3-C Figure 1 . Continued stress and production of ROS, which lead to blood clotting, platelet aggregation, and cytokine (IL-1b) release. Translocation of selectins, VCAMs and ICAMs on the surface of endothelial cells leads to leukocyte adhesion to the endothelium of micro vessels by interaction between ICAM/VCAM with leukocyte a4 and b2 (LFA-1) integrins. Loss of nitric oxide (NO), as a powerful vasodilator agent and inhibitor of leukocyte adhesion to the endothelium, promotes vasoconstriction and enhances leukocyte aggregation. Ischemia and reperfusion trigger production of ROS, which induce pericyte contraction and more microvascular occlusion. Following ischemic inflammation, leukocytes are recruited across the barriers formed by endothelial cells (EC) and the endothelial basement membrane (EBM) and collect in the perivascular space. Release of MMPs from activated leukocytes leads to BBB breakdown and matrix proteolysis, which facilitates leukocyte extravasation. Also, interaction between chemotactic complement subunits (C5a) and mast cell complement receptors (CD88) in the perivascular space causes release of histamine and proteases, participating in BBB breakdown. Parenchymal basement membrane (PBM) and astrocyte end-feet restrict leukocytes from passing freely into CNS neural parenchyma. Ischemia and reperfusion disrupted or rendered the astrocyte endfeet dysfunctional and also the PBM by cytotoxic inflammation. Perivascular macrophages and mast cells produced inflammatory cytokines such as TNF and IL-1b, which helps leukocyte migration across the vessel wall. Injured cells in the brain parenchyma release early proinflammatory signals such as purines (ATP), which lead to production of cytokines and chemokines. Disruption of interactions between neuronal and microglial cells (CX3CL1, CD200) contributes to the proinflammatory milieu. Also, increasing in the extracellular glutamate (Glu) activates GluR1 on microglia that participate in releasing proinflammatory cytokines. chemokine receptor 1 are essential for monocyte infiltration into the ischemic brain (175) (176) (177) . Stimulated M1 macrophages produced proinflammatory cytokines (IL-1b, IL-12, IL-23, and TNF) and the chemokines, ROS and NO (109) (110) (111) (112) (113) . Hence, these proinflammatory cytokines promote the infiltration of leukocytes through the expression of endothelial adhesion molecules and BBB disruption (111) .
Recent findings have shown that critical inflammationrelated miRNAs such as miR-155 and miR-146a modulate the microglia phenotype, and this was inhibited by injection of miR-146a-containig exosomes, whereas miR-155 promoted endotoxin-induced inflammation in mice (178) . In neurological disorders, it has been found that expression of proinflammatory cytokines such as IL-1b and IL-6 is suppressed by miR-146a (179) . Simultaneously with the microglia activation, miR-146a was also found to be overexpressed in infected mouse brain, which demonstrates that miR-146a plays a role in the proinflammatory responses of microglia in brain tissue (180) . It has also been shown that miR-424 inhibits activation of microglia and leads to protective actions against ischemic cerebral injuries (181) . Also, miR-let-7c-5p inhibits microglial activation and translational repression of caspase 3, which causes a protective effect against neuroinflammation following cerebral ischemia (182) . Overexpression of miR-124, one of the most abundant miRNAs in the brain, could increase quiescence of microglia and deactivation of macrophages. During neurological disease, miR-124 expression decreased in the microglia (183) . Also, miR-124 restricts differentiation of primitive macrophages into adult microglia in the brain (183) . Oxygenglucose deprivation (OGD) in the animal model downregulates miR-181c expression but upregulates TNF-a expression, and ectopic expression of miR-181c protected neurons from cell death caused by OGD-activated microglia. Therefore, miR181c controls microglia-mediated neuronal apoptosis by suppressing TNF-a expression after ischemia/hypoxia. (184) . Expression of miR-21 in the microglia is downregulated following hypoxia that influences neuronal apoptosis. The ectopic expression of miR-21 partially protects neurons from cell death caused by hypoxia-activated microglia (185) . miR-9 promotes microglial activation by downregulated expression of the monocyte chemotactic protein-induced protein 1 that is crucial for controlling inflammation. Thus, anti-miR-9 ameliorates microglial activation in vivo (186) .miR-155, a proinflammatory miRNA, targets the suppressor of cytokine signaling 1, which is an anti-inflammatory protein in microglia. Therefore, miR-155 leads to the upregulation of iNOS, IL-6, and TNF-a, which are characteristics of the M1 phenotype (139) . Hence, increasing miR-155 expression leads to microglia-mediated neurotoxic responses, which are associated with the M1 phenotype (187) . miR-124 overexpression led to the downregulation of IL-6, TNF-a, and iNOS as M1-associated markers. Also, miR-124 contributes to the M2 phenotype of macrophages and microglia, and increases TGF-b, arginase-1, and FIZZ1 proteins that are associated with the M2 phenotype (183) .
miRNAs and Neutrophils
Neutrophils are secretory and phagocytic cells of the innate immune system that migrate to cerebral ischemic regions during the first few hours after the onset of ischemia (188) . These cells adhere to the cerebral endothelium and transmigrate into the ischemic brain tissue. Studies showed that neutrophils have a remarkable destructive potential by obstruction of capillary blood flow due to intravascular clogging and the no-reflow phenomenon (189, 190) , breakdown of the BBB by releasing MMP-8 and MMP-9 (84, 191, 192) , and by generating proinflammatory molecules such as ROS and reactive nitrogen species (193) , iNOS, NADPH oxidase, myeloperoxidase, elastase, and cathepsins (84) . Neutrophil access to the brain is usually prevented by the BBB, but under pathological conditions including cerebral ischemia they adhere to the endothelium of the cerebral vessels and infiltrate into the brain parenchyma (84, 194) . In human ischemic stroke, neutrophils extravasate from the leptomeningeal vessels and can eventually reach the brain tissue (195) .
It has been demonstrated that miR-181c could be a potential regulator of neutrophil numbers in acute ischemic stroke, and its plasma concentration positively correlated with neutrophil numbers. Therefore, miR-181c is an immune regulator that modulates the neutrophil-to-lymphocyte ratio following acute ischemic stroke (196) .
miRNAs and Innate Lymphocytes
In the acute phase of cerebral ischemia, unprimed T cells are detrimental and contribute to tissue damage, possibly through IFN-c (197) and ROS (198) . It was shown that lymphocyte-deficient mice are protected in models of focal ischemia (199, 200) . Following ischemia, microglia and macrophages released IL-23, which activate cdT cells and caused them to secrete IL-17 resulting in ischemic injuries (201) (202) (203) . After ischemia, recruited immune cells such as natural killer cells release mediators that contribute to ischemic brain injury. Detrimental effects of natural killer cells are mediated by expression of C-X3-C chemokine receptor 1, which demonstrates the direct cytolytic activity of these cells toward ischemic neurons (204) . Following acute ischemic stroke, miR-181c as an immune regulator modulates the neutrophilto-lymphocyte ratio, and it is negatively correlated with lymphocyte percentage in ischemic patients' plasma (196) .
Mast Cells
Mast cells are brain-resident immune cells located in the meninges and cerebral blood vessels, which are rich in proteases (tryptase, chymase, MMP2, and MMP9), vasoactive molecules (histamine), cytokines (TNF), and anticoagulants (heparin) (109, 110) . After cerebral ischemia, mast cells are activated and release gelatinase that contributes to BBB breakdown and brain edema (205, 206) .
MIRNAS AND IMMUNOMODULATION AS A THERAPEUTIC APPROACH
A large number of mediators are actively orchestrated to suppress the inflammatory responses (207) through promotion of tissue restoration and repair by neurotrophic factors, improvement of anti-inflammatory milieu, and elimination of dead cells (170, 207) . Anti-inflammatory molecules such as IL-10 and TGF-b have a beneficial role, probably by dampening proinflammatory reactions associated with tissue repair (208, 209) .
Following ischemia, expression of TGF-b is increased in microglia and macrophage cells, which demonstrate neuroprotective properties and significant effects on immune cells. TGF-b can also inhibit T helper (type 1 and 2) responses and suppress inflammation. Also, IL-10 production leads to antiinflammatory and neuroprotective activities. Thus, production of TGF-b and IL-10 after ischemia results in antiinflammatory activities, tissue repair, and cytoprotective effects in ischemic brain tissue (210). IL-10 is regulated posttranscriptionally by miR-106a (211) . Furthermore, in the microglia and macrophages, IL-10 and TGF-b are increased by miR-106a and miR-124, respectively (183, 211, 212) . Inhibition of miR-155 triggers IL-10-mediated anti-inflammatory responses, which could significantly contribute to improved poststroke recovery (213) .
Following cerebral ischemia, miR-21 was found to be significantly upregulated and acts as a neuronal precursor cell regulator via the TGF-b signaling pathway. Furthermore, miR-34a may negatively regulate the proliferation of neuronal precursor cells by inhibiting the TGF-b signaling pathway following brain ischemia (214) .
Growth factor production can improve stroke outcome by reducing stroke damage through their antiapoptotic and anti-inflammatory effects, and by promoting neuronal sprouting, neurogenesis, angiogenesis, gliogenesis, and matrix reorganization (215) (216) (217) (218) . Ischemic-activated microglia may release a variety of cytoprotective substances by producing neurotrophic molecules such as IGF-I (a key factor in postischemic neuronal sprouting), BDNF, and several other growth factors (219, 220) . Also, VEGF, which is produced by reactive astrocytes (221) , is an important neurogenic factor with therapeutic potential in ischemic stroke (222) . It has been shown that IGF-1 signaling targets through miR-Let7f antagomir for translation activation, which promotes IGF-1-like neuroprotection in ischemic stroke models (223) .
Following oxygen/glucose deprivation, downregulation of miR-134 alleviates ischemic injury by enhancing BDNF expression in neurons. Therefore, antagomir (antisense oligonucleotide) provides a potential therapeutic agent for cerebral ischemic injury. Downregulation of miR-134 alleviates ischemic injury through enhancement of BDNF and Bcl-2 expression in neurons following oxygen/glucose deprivation (224) . Furthermore, it is reported that miR-107 and miR-30-5p are regulators of BDNF expression, and studies on the precise mechanism of both these miRNAs in BDNF regulation could well be a potential therapeutic agent in neuroprotection following ischemic stroke (225) .
In the adult mouse brain, neurogenesis can be induced via overexpression of miR-210, which is associated with VEGF upregulation (226) . It has been demonstrated that miR-107 increases the expression of VEGF via downregulation of Dicer-1 expression, thereby contributing to poststroke angiogenesis (227) . A novel finding indicates that overexpression of miR-15a inhibits endogenous endothelial fibroblast growth factor 2 and VEGF activities, which leads to suppression of poststroke angiogenesis (228) . After cerebral ischemia, miR15a expression increases in the cerebral vasculature at the penumbral zone (229) . Furthermore, in cultured endothelial cells miR-16, -20a, and -20b target VEGF act as antiangiogenic agents (230) (Fig. 2) .
CONCLUSION
Inflammation is an extremely important part of the pathogenic processes activated by ischemia and reperfusion. Inflammatory signaling is activated in response to harmful stimu li such as arterial occlusion and culminates in the invasion of the brain by blood-borne leukocytes. The main functions of inflammatory responses are to remove pathogens and damaged cells and to aid healing processes (231) , with the ultimate goal of the restoration of homeostasis. However, inflammatory response may be freed from physiological control leading to the development of tissue damage. Therefore, inflammation can cause substantial injuries to the metastable penumbral tissue.
Endogenous circulating miRNAs have been found as potentially useful diagnostic biomarkers because of the less invasive nature of sample procurement. Circulating miRNAs are stable because of their packaging and secretion into the blood within exosomes (232) . Several studies showed that increased circulating miRNAs, such as miR-223 (233) and miR-124 (234) , are associated with acute ischemic stroke occurrence and severity. Hence, in human subjects, decreasing in miR-210 was associated with poorer clinical outcome (235) . However, these miRNAs have potential as a biomarkers and a therapeutic target for ischemic stroke.
miRNAs represent a potentially powerful treatment paradigm. The potential for antagomir therapy has been demonstrated in the acute ischemic stroke. Therefore, miR-181 antagomir effectively reduced the infarction size and protected the penumbra in mice (236) . So, approaches decreasing or blocking miR-181a protect the brain from stroke. Furthermore, inhibition of miR-29b was cytoprotective in cultured neurons subjected to OGD (237) . Hence, this review has shown that inhibition or downregulation of miR-155 (213), miR-134 (224) , and miR-Let7f (223) improved poststroke recovery and neuroprotection by triggering IL-10, BDNF and IGF-1, respectively. Targeting miRNAs that have the capacity to regulate large sets of evolutionary conserved coding genes represents the future of gene therapy.
In the present review we have presented evidence that the functions of miRNAs become increasingly unregulated following ischemic stroke, and alterations of these molecules have profound effects on the downstream target genes that are involved in postischemic inflammation. miRNAs mostly exert their cellular function by inhibition of various downstream mRNA targets. Several studies have indicated the correlation between changes in the expression of miRNAs and postischemic inflammation. Moreover, several miRNAs and their target genes are involved in recovery and repair mechanisms that are involved in neuroprotection following ischemic stroke. These studies explain the contribution of miRNAs in the inflammatory responses following stroke and help us to a better understanding of the processes involved in the pathogenesis of stroke inflammation, where they could be prospective therapeutic agents. The ability of miRNAs to modulate numerous target genes demonstrates their potential therapeutic importance following stroke inflammatory damage. 
